{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P26482",
      "entity_text" : "FIXa",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ01521",
      "entity_text" : "anti-FIXa/FX bispecific antibody",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "In another newly developed approach to the treatment of hemophilia, we generated an anti-FIXa/FX bispecific antibody, emicizumab, which promotes FIXa catalyzed FX activation.",
  "reading_complete" : "2020-08-02T11:54:10Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-02T11:52:35Z",
  "trigger" : "promotes",
  "evidence" : [ "anti-FIXa/FX bispecific antibody, emicizumab, which promotes FIXa" ],
  "pmc_id" : "6524866",
  "score" : 0
}